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Abstract 
Current management of breast cancer (BC) relies on risk stratification based on well-defined 
clinicopathologic factors. Global gene expression profiling studies have demonstrated that BC 
comprises distinct molecular classes with clinical relevance. In this study, we hypothesized that 
molecular features of BC are a key driver of tumour behaviour and when coupled with a novel 
and bespoke application of established clinicopathologic prognostic variables, can predict both 
clinical outcome and relevant therapeutic options more accurately than existing methods. In the 
current study, a comprehensive panel of biomarkers with relevance to BC was applied to a large 
and well-characterised series of BC, using immunohistochemistry and different multivariate 
clustering techniques, to identify the key molecular classes.  Subsequently, each class was 
further stratified using a set of well-defined prognostic clinicopathologic variables. These 
variables were combined in formulae to prognostically stratify different molecular classes, 
collectively known as the Nottingham Prognostic Index Plus (NPI+). NPI+ was then used to 
predict outcome in the different molecular classes with.  Seven core molecular classes were 
identified using a selective panel of 10 biomarkers. Incorporation of clinicopathologic variables 
in a second stage analysis resulted in identification of distinct prognostic groups within each 
molecular class (NPI+). Outcome analysis showed that using the bespoke NPI formulae for 
each biological breast cancer class provides improved patient outcome stratification superior to 
the traditional NPI.  This study provides proof-of-principle evidence for the use of NPI+ in 
supporting improved individualised clinical decision making.  
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Introduction 
Breast cancer (BC), the most common cancer and the second leading cause of cancer death in 
women, represents a heterogeneous group of tumours with varied genotypic and phenotypic 
features, behaviour and response to therapy. This, in addition to numbers and complexity of 
available treatment options, has resulted in decision making difficulties regarding the most 
appropriate treatment choice. Clinical decision making in personalised BC management 
requires robust and accurate risk stratification based not only on outcome prediction but also on 
a biological basis (Clark, 1994). Methods have been developed to assist in predicting patient 
outcome and to support clinical decision making in breast cancer management. Examples of 
such methods include the Nottingham Prognostic Index (NPI) (Balslev et al, 1994; D'Eredita et 
al, 2001; Galea et al, 1992), St Gallen consensus criteria (Goldhirsch et al, 2009), the National 
Comprehensive Cancer Network (NCCN) guidelines (Carlson et al, 2006) and Adjuvant! Online 
(Ravdin et al, 2001).  
The current NPI is based on a combination of histopathological examination of tumour size, 
lymph node stage and tumour grading assembled in a prognostic index formula (Haybittle et al, 
1982) and can be used as a risk stratifier in unselected cohorts of operable early-stage primary 
breast cancer patients. Prognosis worsens as the NPI numerical value increases and by using 
cut-off points patients may be stratified into good, moderate and poor prognostic groups 
(Blamey et al, 2007; Ellis et al, 1987). The NPI has been confirmed after long-term follow-up 
(Galea et al, 1992), validated independently in large multi-centre studies (Balslev et al, 1994; 
Brown et al, 1993) and revised in order to stratify patients into 5 prognostic groups (Blamey et 
al, 2007). However, the NPI cannot reveal the full clinical/survival outcome heterogeneity 
currently observed in BC and would benefit from greater sophistication to support more accurate 
personalised management of BC patients. It is now recognised that the biological characteristics 
of BC are important for clinical management and incorporporation into the NPI could 
significantly improve the delivery of personalised medicine in breast cancer patients, .  
Current data imply that BC is a heterogeneous group of diseases with complex and distinctive 
underlying molecular pathogenesis (Beckmann et al, 1997; Ellis et al, 1999; Lishman & Lakhani, 
1999). Further support for this hypothesis is provided by gene expression profiling (GEP) which 
have identified distinct molecular tumour groups with direct clinical relevance (Darb-Esfahani et 
al, 2009; Nielsen et al, 2010; Parker et al, 2009; Perou et al, 1999; Sorlie et al, 2001; van 't Veer 
et al, 2003; van de Vijver et al, 2002). Whilst this provides further compelling evidence that 
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tumour biology is a key variable required for decision making in personalised BC management, 
the heterogeneity within these groups and its incorportaion with the currently validated variables 
and prognostic indeices add complexity. There is also evidence that individual clinicopathologic 
prognostic factors behave differently in the different molecular subclasses; for instance tumour 
grade and size, which have siginificant prognostic value in the luminal/estrogen receptor 
positive classes, show a limited prognostic power in HER2-positive (Foulkes et al, 2009; 
Foulkes et al, 2010) and basal-like tumours (Rakha et al, 2010). 
Although available data support incorporation of GEP, particularly multigene assays, in specific 
clinical settings, the difficulty in the integration of the clinicopathologic variables with the 
molecular assays, the reproducibility and cost limit the clinical utility of this technology. An 
alternative approach is to initially classify BC into distinct molecular classes using a panel of 
proteins with known relevance to BC utilizing the robust commonplace technology, 
immunocytochemistry, applied to routine formalin fixed paraffin embedded tumour samples.  
 
As previously reported (Abd El-Rehim et al, 2005; Green et al, 2013; Soria et al, 2010), seven 
core breast cancer classes, were identified by evaluation of the expression levels for a selective 
panel of 25 BC-related biomarkers determined using immunohistochemistry and supervised 
classification approaches based on the naïve Bayes classification performance (Soria et al, 
2008). To make this classification easily applicable in routine practice, the number of markers 
was further reduced and 10 markers were found to be the minimum number which is required to 
retain the classification. This formed the basis of the development of a fuzzy rule induction 
algorithm (using the methodology previously described in Rasmani et al (2009)) to classify the 
breast tumours into one of the seven classes (Abd El-Rehim et al, 2005; Green et al, 2013; 
Soria et al, 2010). The core molecular classes identified include three luminal classes tumour 
characterised by high luminal Ck7/8 and hormone receptor expression. Luminal A and Luminal 
B tumours show high expression of CK7/8, ER, HER3 and HER4 but are separated by lower 
levels of PgR expression in Luminal B. Luminal N tumours show differential expression of HER3 
and HER4. The two basal classes of tumour, characterised by high basal expression, are 
separated by p53 protein expression levels: high p53 (Basal – p53 altered) or low p53 (Basal – 
p53 normal). The two HER2+ classes are characterised by HER2 over-expression and are 
either positive or negative for the expression of ER. These distinct molecular classes of BC 
showed significant association with patient outcome.   
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In this study, we examine the hypothesis that molecular features of BC are a key driver of 
tumour behaviour and that the influence of established prognostic will vary between classes. As 
a consequence application of established clinicopathologic prognostic variables will require 
development of bespoke prognostic indices to improve prediction of both clinical outcome and 
relevant therapeutic options. To examine this hypothesis a comprehensive panel of biomarkers 
with relevance to BC, described above, has been applied to a large and well-characterised 
series of BC, using immunohistochemistry and different multivariate clustering techniques, to 
identify the key molecular classes, phase 1 of Nottingham Prognostic Index Plus (NPI+) 
classification.  Subsequently, each class was further stratified using a set of well-defined 
prognostic clinicopathologic variables. These variables were combined in bespoke formulae to 
prognostically stratify different molecular classes, NPI+ classification phase 2.  Thus NPI+ is 
based on a two tier evaluation; the initial assement determines the biological class of the tumour 
and is subsequently combined with a second level analysis of traditional clinicopathologic 
prognostic variables resulting in tailored (bespoke) NPI-like formulae for each biological class.  
 
Patients and Methods 
Patients  
A series of 1,073 patients from the Nottingham Tenovus Primary Breast Carcinoma Series, 
aged 70 years or less, presenting with primary operable (stages I, II and III) invasive breast 
cancer between 1986-98 were used. This is a well-characterised consecutive series of patients 
who were uniformly treated according to standard clinical protocols (Abd El-Rehim et al, 2005; 
Rakha et al, 2008). All tumours were less than 5 cm diameter on clinical/pre-operative 
measurement and/or on operative histology (pT1 and pT2).  Women aged over 70 years were 
not included because of the increased confounding factor of death from other causes and 
because primary treatment protocols for these patients often differed from those for younger 
women. Adjuvant systemic therapies were offered according to the Nottingham Prognostic 
Index (NPI) (Galea et al, 1992) and hormone receptor (HR) status (Galea et al, 1992). The NPI 
was calculated using the following formula: NPI = histological grade (1-3) (Rakha et al, 2008) + 
lymph node (LN) stage (1-3; 1= negative, 2=1-3 nodes positive, 3= ≥4 nodes positive) + (tumour 
size/cm x 0.2). No systemic therapy was offered to patients in the Good prognostic groups (NPI 
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≤3.4). Patients in the Moderate I group (NPI 3.41-4.4) with HR-positive tumours were offered 
hormonal therapy. Patients in the Moderate II (4.41-5.4) and Poor (NPI >5.41) groups received 
hormone therapy for HR-positive tumours and cytotoxic therapy (classical cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF)) for HR-negative tumours if and the patient is fit enough 
to tolerate chemotherapy. Hormonal therapy was given to 420 patients (39.0%) and 
chemotherapy to 264 (24.5%). Data relating to survival was collated in a prospective manner for 
those patients presenting after 1989 only. Breast cancer specific survival (BCSS) was defined 
as the interval between the operation and death from breast cancer, death being scored as an 
event, and patients who died from other causes or were still alive were censored at the time of 
last follow-up. This study was approved by the Nottingham Research Ethics Committee 2 under 
the title `Development of a molecular genetic classification of breast cancer'. 
 
Biomarker assay 
Immunohistochemical reactivity for 10 proteins, with known relevance in breast cancer including 
those used in routine clinical practice, were previously determined using standard 
immunocytochemical techniques on tumour samples prepared as tissue microarrays. These 
markers were chosen from a comprehensive panel of 25 markers used in our previously study 
(Abd El-Rehim et al, 2005) as  the minimum number of markers that can maintain class 
membership and identify the same molecular classes (Green et al, 2013). The biomarkers used 
for classification were Estrogen Receptor (ER), Progesterone Receptor (PgR), cytokeratin (CK) 
5/6, CK7/8, epidermal growth factor receptor (EGFR; HER1), c-erbB2 (HER2), c-erbB3 (HER3), 
c-erbB4 (HER4), p53, and Mucin 1. Levels of immunohistochemical reactivity were determined 
by microscopic analysis using the modified Histochemical score (H-score), giving a 
semiquantitative assessment of both the intensity of staining and the percentage of positive 
cells (values between 0-300) (Goulding et al, 1995; McCarty et al, 1985). For HER2, the American 
Society of Clinical Oncology/College of American Pathologists Guidelines Recommendations for 
HER2 Testing in Breast Cancer were used for assessment (Wolff et al, 2007). Equivocal (2+) 
cases were confirmed by CISH as previously described (Garcia-Caballero et al, 2010).  
 
Identification of Biological Class 
As previously reported (Soria et al, 2010), six core breast cancer classes, with an additional 
unclassifiable class, were obtained using a consensus clustering approach between different 
clustering methods. Briefly, four-step methodology for elucidating core, stable classes of data 
from a complex, multi-dimensional dataset was as follows:  1) A variety of clustering algorithms 
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were run on the data set including Hierarchical, K-means, Partitioning around medoids, 
Adaptive resonance theory and Fuzzy c-means.  2) Where appropriate, the most appropriate 
number of clusters was investigated by means of cluster validity indices.  3) Concordance 
between clusters, assessed both visually and statistically, was used to guide the formation of 
stable ‘core’ classes of data.  4) A variety of methods were utilised to characterise the 
elucidated core classes. Concordance among solutions was evaluated using the Cohen’s kappa 
coefficient k. For inspection of the patient characteristics in each class, the distribution of each 
variable in the class was compared with its distribution in the total sample, using boxplots. A 
conventional multi-layer perceptron artificial neural network model was utilised such that 
individual H-scores derived from the tissue microarray analysis of the clinical samples were set 
as inputs and the class was set as the output using Boolean notation. This allowed the 
identification of markers that drive membership of a given class and that discriminate the class 
from the others. 
Three luminal subgroups (Luminal-A [no=370], Luminal-N [no=146] and Luminal-B [no=123]), 
two basal classes (basal-p53-altered [no=126] and basal-p53-normal [no=87]) and a HER2-
positive class (HER2+ [no=145]) were highlighted. In a subsequent study (Green et al, 2013) 
the HER2+ class was divided into two subgroups (HER2+/ER+ [no= 60] and HER2+/ER- 
[no=85]).  
 
Development of NPI formulae for each Biological Class 
A Cox regression analysis was performed for the overall population for a selection of available 
and well-established histopathologic prognostic factors.  The variables tested were coded using 
a numerical categorical or continuous, depending on the variable, method.  The variables 
included were: Number of positive nodes (N) (including nodal stage (St)), Tumour Size (Sz), 
Tumour Grade (including its components namely Tubule formation, Nuclear pleomorphism and 
Mitotic index (M) (Rakha et al, 2008)), LymphoVascular Invasion (LVI), Estrogen Receptor 
status (ER), Progesterone Receptor status (PgR) and HER2 status. The NPI formulae were 
used to determine the prognostic effect in each biological class. The NPI+ score is determined 
by utilisation of the Beta values generated by the COX regression.  These beta values indicate 
the magnitude of the influence of the hazard. 
 
Survival analysis 
After identification of the relevant parameters and their influence upon the prognostic model and 
within the context of each class, the individuals of the populations were assigned a NPI+ value 
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in order to stratify them into different subgroups of prognostic relevance. In this preliminary 
work, the groups were assigned according to the integer value of the NPI+ score. This helped to 
ultimately stratify the cohorts of patients of each biological class in a Kaplan-Meier curve.  
 
 
Results 
Biological Class 
In this study, using a consensus clustering approach and a panel of routinely applicable 
immunohistochemical markers with relevance to breast cancer, seven core molecular breast 
cancer classes were identified. These classes included 370 patients in class 1 (Luminal A); 146 
class 2 (Luminal N); 123 class 3 (Luminal B); 126 class 4 (basal p53 altered); 87 class 5 (basal 
p53 normal); 60 class 6 (HER2+ / ER+), and 85 class 7 (HER2+ / ER-).   
 
Development of NPI formulae for each class 
After successive removal of the least significant (i.e. with p values above 0.2) parameters during 
different steps, the final factors with the most significant results, according to their beta value in 
the Cox regression analysis, were identified. The proportional hazard ratio Cox regression 
identified six clinicopathologic prognostic factors of importance within the population in 
predicting breast cancer specific survival (BCSS): N (nodal number), St (stage), Sz (size), M 
(mitosis), LVI and PgR. Once these factors were identified, the population was split into the 
biological classes, as determined above, and Cox regression analyses were performed 
independently for each class in order to obtain the most significant clinicopathologic prognostic 
factors and their β-value in the context of the classes. Kaplan-Meier analysis showed that using 
formulae, based on N, Sz, St, M, LVI and PgR, for each biological breast cancer class provides 
improved and highly significant patient outcome stratification compared to the traditional NPI 
(Fig 1a-g).  These variables were combined to form formulae that vary among different classes 
leading to bespoke NPI-like formulae for each of the seven biological classes forming a new 
biomarker based prognostic index (NPI+). This NPI+ was then used to predict outcome (BCSS) 
in the different molecular classes and the NPI+ outcome prediction was compared to that 
achieved by the traditional NPI in each of the biological classes (Fig 1a-g). In addition to 
improved outcome prediction using NPI+ compared to the traditional NPI in each class, NPI+ 
provided more clinically relevant stratification with splitting of each class into 2 or 3 groups 
compared to the six classes of NPI. 
9 
 
 
Prediction of adjuvant therapy benefit 
Although the current study is not derived from a randomised clinical trial samples, the cases 
were stratified based on adjuvant systemic therapy in an attempt to assess the potential value of 
using NPI+ to predict outcome in the different classes. The number of the patients receiving 
either endocrine therapy or chemotherapy in each of the NPI+ classes is summarised in Table 
2.. When the cohort was stratified according to systemic therapy, NPI+ was found to predict 
good versus adverse outcome for all of the biological classes in both hormone therapy treated 
patients (Figure 2) and chemotherapy treated patients (Figure 3) with the exception of 
chemotherapy benefit in class 5 (Basal p53 normal) in which few deaths were observed in the 
group as a whole (Figure 3c). This approach is superior to use of the traditional NPI (Figure 4) 
which provides overall patient stratification but lacks similar ability to predict adverse outcome 
effectively in specific molecular classes. 
 
 
Discussion 
Improved tailoring of treatment for breast cancer requires integration of clinical pathologic and 
cancer biological information to ensure all known variables which could potentially influence 
patient outcome and response to therapeutic treatments are considered.  Subsequently, there 
has been increasing interest in the clinical utility of multigene assays, such as the Oncotype 
DX® (Paik et al, 2004) and the MammaPrint® test (van 't Veer et al, 2002), and their integration 
into breast cancer management strategies in certain clinical settings.  Although the concept of 
molecular taxonomy of breast cancer using global gene expression profiling has attracted 
attention of the scientific community, their incorporation into routine clinical decision making did 
not prove successful for a number of reasons.  These include cost, reproducibility, validation 
and lack of of suitability to routine clinical settings.  
Previously, we (Abd El-Rehim et al, 2005) (Green et al, 2013) and others (Ambrogi et al, 2006; 
Callagy et al, 2003) have used immunohistochemistry (IHC) and tissue microarray (TMA) 
technology to develop a proposal for a modern molecular classification of human breast cancer 
comparable to that produced by gene expression microarrays. By way of contrast, our 
methodology is expected to provide not only a simple and cost-effective approach but also a 
robust, feasible and reproducible method for breast cancer risk stratification. In this study, we 
hypothesised that the combination of molecular taxonomy using a panel of IHC biomarkers with 
traditional prognostic clinicopathologic variables can produce a ‘state of the art’ approach of risk 
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stratification in a reproducible and balanced way. This approach is driven by our improved 
understanding of breast cancer biology and its impact on tumour behaviour and response to 
therapy, in addition to the expanding field of systemic and targeted therapy and subsequent 
difficulty in predicting outcome in these complex circumstances.  
Initially, the combined protein expression profiles of 25 well-characterised biologically relevant 
biomarkers were assessed. These included proteins involved in different cellular functions and 
disease pathways including cell proliferation, adhesion, signal transduction and structural 
proteins. Using a consensus of clustering methodology and modelling techniques, we have 
developed a clinically based classification of breast cancer based on 10 biomarkers (Green et 
al, 2013). This has confirmed seven classes, comparable to those identified with gene 
expression analysis. Subsequently, we have further developed the algorithms in order to reduce 
the number of biomarkers required for classification to a maximum of ten biomarkers. These key 
biological phenotypes of breast cancer can be identified using standard, widely available 
immunocytochemistry technology and are associated with significantly different patient 
outcomes. Also of importance is the observation that 93% of breast cancer cases clearly exhibit 
core class membership criteria, while only 7% remain unclassified. In addition, we believe that 
using this classification system provides a reflection of the complex molecular portrait of BC 
more than that could be obtained using the three marker panel (ER, PgR, HER2) assessed in 
routine practice.  In the second phase, we used the existing clinicopathologic variables to stratify 
each biological class into clinically distinct subgroups using bespoke NPI -like formulae, known 
as the NPI+. The parameters used for the NPI+ for each of the 7 core molecular class is not 
only different for each class but also incorporate additional well validated variables such as LVI 
(Rakha et al, 2012) and PgR (Prat et al, 2013) that were not considered in the generation of the 
traditional NPI index. The use of such formulae not only overcomes problems associated with 
the variable prognostic power of each individual clinicopathologic factors in the different 
molecular classes but also provides a way of incorborating biological and clinical variables in a 
scientifically and clinically relevant way (Dunkler et al, 2007).  
The aim of the study is not revolution but evolution; the aim is not to replace current proven and 
established methods but to build on and improve the current prognostic methods by combining 
the well-established powerful clinicopathologic variables with novel biomarker information. In 
developing our prognostic toolkit we aimed to provide an assay compatible with routinely 
processed formalin fixed paraffin embedded tissue, offering a level of sensitivity and predictive 
capabilities far better and more sophisticated than present classification systems. Our results 
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demonstrate that NPI+ not only provides prognostic information with consideration of biological 
features but NPI+ also performs better than traditional NPI and can subsequently help guiding 
treatment decision in a personalised fashion (Table 3). We believe NPI+ combines the breadth 
of AdjuvantOnline! (Olivotto et al, 2005) with greater direct clinical validation, whilst also having 
depth of clinical and biological relevance of the current commercial solutions. NPI+ will enable a 
more sophisticated personalised treatment tool for breast cancer patients by providing: 1) 
Improved prognostic analysis, 2) Predict risk of disease recurrence, 3) Provide health economic 
savings through appropriate targeting of treatment, 4) NPI+ uses routine clinical samples and 
robust laboratory methods integrating easily into current international clinical practice.  
This study however has limitations. Therapy decisions of the current study patients’ cohort were 
based on similar prognostic markers at the time point of the first diagnosis with the potential of 
adjuvant therapy confounding effect. There may be an underrepresentation of cases without 
chemotherapy in the group of patients with a low initial NPI (good prognostic group), likewise 
the group of patients without a chemotherapy in patients with a high initial NPI (poor prognostic 
group) is rather low. This is a recognised limitation of prognostic marker and risk stratifiers 
assessment in the current era in which depriving patients from adjuvant treatment cannot be 
ethically justified. Initial results of this study indicate prognostic value when patients were 
stratified based on systemic therapy. Currently additional cohorts are being tested to provide 
sufficient number in the different treatment subgroups. Although phenotypic classification into 
core luminal, basal and HER2 classes is possible using smaller panels of 3 to 5 antibodies 
(Carey et al, 2006; Cheang et al, 2008), such limited panels cannot further sub classify these 
core groups. Our study clearly demonstrates that using a larger panel of 10 biomarkers a higher 
level of stratification is achieved which may have direct and important clinical relevance. 
In conclusion, this study provides proof-of-principle evidence for the development of a novel 
prognostic index (NPI+) that combines both established clinicopathologic and biological features 
of breast cancer. Validation in different national and international tumour series is currently 
underway. Furthermore, its clinical utility and impact on health economics will be typically 
assessed in a prospective randomised clinical trial. 
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Tables 
Table 1. Clinicopathological parameters of the seven breast cancer biological classes 
LN=lymph node (stage 1=negative LN, stage 2=1-3 positive LN, stage 3= ≥4 positive LN).  
 
Parameter 
Biological Class 
Luminal A 
(no=370) 
Luminal N 
(no=146) 
Luminal B 
(no=123) 
Basal –  
p53 
altered 
(no=126) 
Basal –  
p53 
normal 
(no=87) 
HER2+/ER+ 
(no=60) 
HER2-
/ER- 
(no=85) 
Cramer’s 
V(M, 
2000) 
(P-
value) 
 
No (%) No (%) No (%) No (%) No (%) No (%) No (%)  
Size 
       
 
<15mm 106 (28.6) 45 (30.8) 27 (22.0) 15 (11.9) 10 (11.5) 6 (10.0) 10 (11.8) 0.199 
(< 0.01) 
≥15mm 264 (71.4) 101 (69.2) 95 (77.2) 111 (88.1) 77 (88.5) 54 (90.0) 75 (88.2)  
Grade         
1 79 (21.4) 41 (28.1) 20 (16.3) 1 (0.8) 0 (0) 1 (1.7) 1 (1.2) 0.405 
2 160 (43.2) 80 (54.8) 48 (39.0) 4 (3.2) 8 (9.2) 13 (21.7) 10 (11.8) (< 0.01) 
3 131 (35.4) 25 (17.1) 54 (43.9) 121 (96.0) 79 (90.8) 46 (76.6) 74 (87.0)  
LN Stage         
1 227 (61.4) 100 (68.5) 69 (56.1) 82 (65.1) 56 (64.4) 29 (48.3) 38 (44.7) 0.116 
(< 0.01) 
2 120 (32.4) 37 (25.3) 37 (30.1) 33 (26.2) 24 (27.6) 25 (41.7) 33 (38.8)  
3 22 (5.9) 9 (6.2) 15 (12.2) 11 (8.7) 7 (8.0) 6 (10.0) 14 (16.5)  
NPI         
Excellent 54 (14.6) 29 (19.9) 14 (11.4) 0 (0) 0 (0) 1 (1.7) 1 (1.2) 0.203 
Good 93 (25.1) 49 (33.6) 21 (17.1) 2 (1.6) 5 (5.7) 5 (8.3) 4 (4.7) (< 0.01) 
Moderate 1 103 (27.8) 34 (23.3) 30 (24.4) 50 939.7) 22 (25.3) 18 (30.0) 24 (28.2)  
Moderate 2 70 (18.9) 24 (16.4) 35 (28.5) 45 (35.7) 37 (42.5) 18 (30.0) 26 (30.6)  
Poor 39 (10.5) 8 (5.5) 15 (12.2) 20 (15.9) 21 (24.1) 13 (21.7) 19 (22.4)  
Very Poor 8 (2.2) 2 (1.4) 5 (4.1) 7 (5.6) 1 (1.1) 4 (6.7) 9 (10.6)  
Chemotherapy         
No 319 (90.1) 128 (90.8) 111 (94.1) 59 (50) 42 (52.5) 45 (78.9) 47 (58) 0.201 
(<0.01) Yes 35 (9.9) 13 (9.2) 7 (5.9) 59 (50) 38 (47.5) 12 (21.1) 34 (42) 
Hormone therapy         
No 185 (52.1) 90 (62.9) 44 (37.6) 105 (84.6) 60 (75) 24(40) 66 (77.6) 0.362 
(<0.01) Yes 170 (47.9) 53 (37.1) 73 (62.4) 21 (15.4) 20 (25) 36 (60) 19 (22.4) 
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Table 2. The number of patients in NPI+ classes receiving adjuvant systemic therapy 
 
 Endocrine therapy Chemotherapy 
Yes No Yes No 
Luminal A 
Group 1 88 139 13 213 
Group 2 62 18 13 67 
Group 3 10 5 5 10 
Luminal N 
Group 1 35 71 7 98 
Group 2 10 4 4 10 
Luminal B 
Group 1 23 29 0 52 
Group 2 40 4 6 39 
Basal – p53 altered 
Group 1 15 63 37 41 
Group 2 4 21 21 5 
Basal – p53 normal 
Group 1 11 32 19 24 
Group 2 6 19 15 10 
HER2+/ER+ 
Group 1 17 10 4 23 
Group 2 16 8 8 16 
HER2+/ER- 
Group 1 18 23 12 29 
Group 2 4 11 9 6 
Group 3 3 6 7 2 
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Table 3. Comparison of the traditional NPI with NPI+ 
 
Traditional NPI NPI+ 
Applicable to all forms of 
primary invasive breast cancer  
Applicable to all forms of 
primary invasive breast cancer 
but initial phase of NPI+ 
classification categorises into 
one of seven molecular classes 
Applies equal weighting of 
prognostic factors (histological 
grade, lymph node stage and 
tumour size) to all types of 
invasive breast cancer without 
consideration for molecular 
classes  
 
Second phase of NPI+ 
classification uses prognostic 
factors and weighting relevant 
to each molecular class. 
Additional prognostic factors 
such as lymphovascular and 
invasion progesterone receptor 
are included in the formulae 
Stratifies in terms of expected 
prognosis 
Stratifies effectively in each 
molecular class identifying 
patients whose outcome is as 
expected following standard 
therapy versus those who have 
a suboptimal outcome and may 
benefit from alternative / 
additional forms of treatment 
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Figure legends 
Figure 1 - Patient stratification with the classic NPI (left) compared with NPI+ (right) in each of the 
biological classes. a) class 1 Luminal A, b) class 2 Luminal N, c) class 3 Luminal B, d) class 4 Basal p53 
altered e) class 5 Basal p53 normal f) class 6 HER2+/ER+ g) class 7 HER2+/ER-. GPG= good prognostic 
group, M1 & M2= moderate prognostic groups 1&2, PPG= poor prognostic group, VPPG= very poor 
prognostic group. Time is shown in months. 
Figure 2 - Stratification using NPI+ of those patients who received adjuvant chemotherapy in HER2 
positive (regardless of ER expression; left) and HER2 positive ER-negative (right) classes.  Time is shown 
in months. 
Figure 3 - Stratification using NPI+ of those patients in the various classes who received adjuvant 
chemotherapy for groups a) luminal (1+2 +3), b) basal (4+5), c) two basal groups - patients with Basal 
p53 normal tumours had a good survival overall and no additional stratification could be achieved. d) 
HER2 (6+7),e) HER2+/ER+ and f) ER+/ER-. There were too few luminal cases receiving chemotherapy to 
allow development of NPI+ formulae for each of the luminal groups. It can be seen that NPI+ identifies 
patients with favourable versus poor outcome in all classes assessable apart from the Basal p53 normal 
class. Time is shown in months. 
 
Figure 4 - Survival for each of the classic NPI groups in the whole patient set. Time is shown in months. 
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N=11
N=29 p = 0.00028
Patient stratification with NPI+ formula – both HER2 positive groups merged 
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Figure 3a 
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Figure 3b 
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Patient stratification with NPI+ formula – both Basal groups merged 
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Figure 3c 
Cumulative Proportion Surviving (Kaplan-Meier)
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Figure 3d 
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Figure 3e 
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Figure 4. 
